The Influenza Diagnostics Market is evolving beyond standalone influenza testing toward integrated respiratory diagnostics. The growing circulation of multiple respiratory viruses has increased the value of tests capable of identifying several pathogens simultaneously. This transition is creating opportunities for manufacturers to develop multiplex platforms, next-generation molecular assays, and connected diagnostic solutions.

According to Market Research Future, the global market was valued at USD 1.94 billion in 2025 and is projected to grow to USD 3.53 billion by 2035 at a CAGR of 6.15% during 2026–2035.

Multiplex respiratory panels represent one of the most attractive opportunities in the market. Combination tests can detect influenza alongside COVID-19, RSV, and other respiratory pathogens from the same sample. This broader testing capability can help clinicians distinguish between illnesses with similar symptoms and support more informed treatment decisions.

The increasing adoption of molecular diagnostics is strengthening this opportunity. RT-PCR remains an established technology in hospital laboratories, while LAMP and CRISPR-based platforms are introducing alternative approaches for decentralized testing. MRFR reports that CRISPR-based assays are projected to grow at a 10.0% CAGR through 2035.

Another emerging opportunity is connected diagnostics. Modern analyzers can generate digital testing information that may support disease surveillance and epidemiological monitoring. When appropriately anonymized and managed, diagnostic data can contribute to syndromic surveillance systems and help public-health organizations identify changes in respiratory disease activity.

Veterinary diagnostics may also provide additional opportunities. Influenza viruses affect both human and animal populations, and increased attention to zoonotic disease surveillance is encouraging demand for testing across veterinary and agricultural environments. Companies with platforms suitable for multiple sample types may be able to expand their addressable markets.

The future market will also be influenced by artificial intelligence. AI-enabled systems can assist with workflow optimization, quality-control monitoring, and automated interpretation. These capabilities may help laboratories increase testing capacity without proportionally increasing staffing requirements.

Leading companies active in the market include Roche Diagnostics, Abbott Laboratories, QuidelOrtho Corporation, Hologic, bioMérieux, and Cepheid.

Overall, the industry is moving toward integrated respiratory testing that combines speed, accuracy, multiplex capability, automation, and decentralized access. Manufacturers that successfully combine these characteristics can capture opportunities created by the changing requirements of modern influenza surveillance and diagnosis.